Peptidomimetic macrocycles and formulations thereof

Abstract

Aqueous pharmaceutical formulations, for parenteral administration, comprising peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof wherein the peptidomimetic macrocycle binds to MDM2 and/or MDMX proteins are disclosed. Also disclosed are methods of treating diseases and disorders using the aqueous pharmaceutical formulations disclosed herein.

What is claimed: 
     
         1 - 293 . (canceled) 
     
     
         294 . An aqueous pharmaceutical formulation in a unit dosage form comprising:
 (i) a peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof, wherein the peptidomimetic macrocycle;   (ii) a buffering agent;   (iii) a stabilizing agent that is polysorbate 20;   (iv) a tonicity agent that is trehalose;   wherein the peptidomimetic macrocycle has a Formula I:   
       
         
           
           
               
               
           
         
         wherein 
         each D, Xaa 5 , Xaa 6 , Xaa 8 , Xaa 9 , and E is independently an amino acid; 
         each E is independently selected from Ala, D-Ala, Aib, Sar, and Ser; 
         [D] v  is Leu 1 -Thr 2 ; 
         Xaa 3  is Phe; 
         Xaa 7  is Trp; 
         Xaa 10  is Leu; 
         each R 1  and R 2  is independently alkyl; 
         L is a macrocycle-forming linker; 
         R 7  is —H; 
         R 8  is —H; and 
         w is an integer from 1-10. 
       
     
     
         295 . The aqueous pharmaceutical formulation of  claim 294 , wherein the peptidomimetic macrocycle has a length value of from 14 to 20 amino acids. 
     
     
         296 . The aqueous pharmaceutical formulation of  claim 294 , wherein the peptidomimetic macrocycle has a von Heijne value of from 2 to 9. 
     
     
         297 . The aqueous pharmaceutical formulation of  claim 294 , wherein the peptidomimetic macrocycle has a percent alanine content of from 15% to 40%. 
     
     
         298 . The aqueous pharmaceutical formulation of  claim 294 , wherein a first, second, third, fourth, fifth, or sixth C-terminal amino acid of the peptidomimetic macrocycle is hydrophobic. 
     
     
         299 . The aqueous pharmaceutical formulation of  claim 294 , wherein the peptidomimetic macrocycle comprises an α-helix. 
     
     
         300 . The aqueous pharmaceutical formulation of  claim 294 , wherein the pharmaceutically acceptable salt of the peptidomimetic macrocycle is a sodium, potassium, lithium, calcium, zinc, or magnesium salt. 
     
     
         301 . The aqueous pharmaceutical formulation of  claim 294 , wherein total peptidomimetic degradation products formed in the aqueous pharmaceutical formulation is less than 1.0% when stored at a temperature of 40° C. for a period of one month. 
     
     
         302 . The aqueous pharmaceutical formulation of  claim 294 , wherein an osmolarity of the aqueous pharmaceutical formulation is from about 250 to about 1000 milliosmoles per kilogram. 
     
     
         303 . The aqueous pharmaceutical formulation of  claim 294 , further comprising glucose, fructose, galactose, sucrose, lactose, maltose, or a mixture thereof. 
     
     
         304 . The aqueous pharmaceutical formulation of  claim 294 , wherein the aqueous pharmaceutical formulation has a pH from about 6.0 to about 8.0. 
     
     
         305 . The aqueous pharmaceutical formulation of  claim 294 , wherein the aqueous pharmaceutical formulation has a pH from about 4.0 to about 9.0. 
     
     
         306 . The aqueous pharmaceutical formulation of  claim 294 , wherein the peptidomimetic macrocycle has a molecular weight in the range of 1800-2000 D. 
     
     
         307 . A method of making an aqueous pharmaceutical formulation comprising adding greater than 15 mg/mL of a peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof to water or an aqueous solution, wherein the aqueous pharmaceutical formulation comprises less than 2% w/v of any micelle forming agent. 
     
     
         308 . The method of  claim 307 , wherein the peptidomimetic macrocycle is capable of binding to the MDM2 and/or MDMX proteins. 
     
     
         309 . The method of  claim 307 , comprising adding a sodium salt of the peptidomimetic macrocycle to water or an aqueous solution. 
     
     
         311 . The method of  claim 307 , further comprising adjusting the pH of the solution comprising the buffering agent and the stabilizing agent during the addition of the peptidomimetic macrocycle. 
     
     
         312 . The method of  claim 307 , further comprising filtration of the aqueous pharmaceutical formulation obtained after the addition of the peptidomimetic macrocycle to the aqueous solution. 
     
     
         313 . The aqueous pharmaceutical formulation of  claim 294 , wherein the aqueous pharmaceutical formulation is suitable for administration to a subject without dilution.